Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Score, Valuation & Financial Research

Neumora Therapeutics, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for NMRA

Neumora Therapeutics, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 0.47. These figures are a research snapshot, not a buy or sell recommendation.

What Neumora Therapeutics, Inc. Common Stock does

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Neumora Therapeutics is a clinical-stage biotechnology company that focuses on the research and development of novel precision medicines for brain diseases. The company does not currently generate product revenue and relies on capital raises and potential future licensing or commercialization agreements to fund its operations.

Products and services

  • The company is developing a pipeline of precision neuroscience programs targeting neuropsychiatric disorders and neurodegenerative diseases, including navacaprant (NMRA-140) for major depressive disorder and bipolar depression.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company relies on various unnamed third-party CROs to conduct clinical trials and manage research activities. Source
  • Contract Manufacturing Organizations (CMOs) — The company relies on unnamed third-party CMOs for the manufacturing of drug candidates for clinical trials. Source

Business relationships and partnerships

  • Amgen Inc. — Strategic collaboration for the development and commercialization of certain neuroscience programs. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies — The company competes with various established pharmaceutical and biotechnology companies developing treatments for neuropsychiatric and neurodegenerative diseases. Source

Business strengths to evaluate

  • Precision medicine approach integrating data science and translational neuroscience Source

Business risks and research considerations

  • History of net losses and expectation of continued losses Source
  • Dependence on success of clinical-stage product candidates Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

NMRA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.47
Market capitalization:
86.88M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -212.75M
Free cash flow:
USD -206.44M
Cash:
USD 116.83M
Total debt:
USD 340K
EPS:
USD -1.23

What stands out

  • Free cash flow is USD -206.44M, negative for the stored period.
  • The balance sheet shows USD 116.83M of cash versus USD 340K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 116.49M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for NMRA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can NMRA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is NMRA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for NMRA to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of NMRA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-08.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research NMRA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.